Next-Generation Probiotics: an extensive molecular and clinical review of Live Biotherapeutic Products

The human gastrointestinal tract is a bioreactor of immense complexity, housing over 1014 microorganisms that orchestrate a symphony of metabolic and immunological signals across the host’s systemic landscape. While conventional probiotics have historically relied on a limited repertoire of fermented food-derived strains like Lactobacillus and Bifidobacterium, the scientific community is shifting toward Next-Generation Probiotics (NGPs). These organisms, often identified through high-resolution metagenomic screening and functional culturomics, are native to the human gut and possess specialized functional niches that conventional strains lack. This review provides an exhaustive analysis of the molecular mechanisms through which NGPs like Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bacteroides fragilis may modulate host physiology. We explore the SCFA-epigenetic axis, the activation of G-protein coupled receptors (GPCRs), the reinforcement of the mucosal barrier through tight-junction upregulation via specific outer membrane proteins, and the suppression of pro-inflammatory cytokines such as IL-17 and TNF-alpha, carefully differentiating preclinical in vitro and murine findings from established human clinical evidence. Furthermore, we evaluate the industrial challenges of producing Extremely Oxygen-Sensitive (EOS) bacteria and the stringent regulatory hurdles—including Good Manufacturing Practice (GMP) standards—inherent in the transition from dietary supplements to pharmaceutical-grade Live Biotherapeutic Products (LBPs). Finally, we highlight significant translational limitations, including colonization resistance and inter-individual variability, emphasizing the need for personalized microbiome therapeutics.